CAMP4 Therapeutics raises $75 million in IPO, advances RNA therapies for rare diseases, and partners with BioMarin. Analysts ...

Cantor Fitzgerald analyst Olivia Brayer maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by ...

Matteis covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical ... However, on October 31, BMO Capital maintained a Hold rating on Neurocrine (NASDAQ: NBIX). NBIX market cap ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Free Report) saw a large increase in short interest during the month of October. As of October 15th, there was short interest totalling 5,590,000 shares ...

Blue Trust Inc. raised its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 504.9% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 859 shares ...

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) had its price target dropped by equities research analysts at Citigroup from $93.00 to $81.00 in a research report issued on Wednesday, Benzinga ...

On October 31, 2024, Biomarin Pharmaceutical Inc (NASDAQ:BMRN) filed its 10-Q report, providing a snapshot of the company's financial health and operational performance. As a biotechnology firm ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Free Report)’s stock price reached a new 52-week low during trading on Wednesday following a weaker than expected earnings announcement. The stock ...

Evercore ISI analyst Cory Kasimov maintained a Buy rating on Neurocrine (NBIX – Research Report) today and set a price target of $175.00.

Piper Sandler analyst Christopher Raymond assigned a Buy rating to Amgen (AMGN – Research Report) today and set a price target of ...

In a report released yesterday, Olivia Brayer from Cantor Fitzgerald assigned a Buy rating to Amgen (AMGN – Research Report), with a ...